STERIS plc

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

STERIS plc $STE Shares Sold by Krilogy Financial LLC

AI-generated analysis

πŸ“‰ Krilogy Financial LLC reduced its STERIS stake by 65.7%, selling 3,350 shares to hold a remaining position of 1,752 shares valued at $385,000.

πŸ“ˆ Goldman Sachs Group Inc. increased its holding by 32.3%, acquiring an additional 59,264 shares worth approximately $55 million.

πŸ“Š The stock traded at $215.59 on Monday, sitting below the 200-day moving average of $233.10 but above the 50-day average of $212.77.

πŸ’° STERIS paid a quarterly dividend of $0.63 per share with an ex-dividend date of June 8th, yielding 1.2% annually.

🎯 Analyst consensus remains 'Moderate Buy' with an average price target of $278.00 despite some recent rating downgrades.

πŸ‘” Insider selling occurred as VP John Adam Zangerle and Director Richard C. Breeden sold shares under Rule 10b5-1 trading plans.

🏦 Hedge funds and institutional investors collectively own 94.69% of the company's outstanding stock.

Bullish Signals
  • Goldman Sachs Group Inc. significantly increased its stake by 32.3%, acquiring over $55 million in shares, indicating strong institutional confidence.
  • The company maintains a healthy balance sheet with a current ratio of 2.09 and a low debt-to-equity ratio of 0.25.
  • Analysts maintain an average 'Moderate Buy' rating with a consensus price target of $278.00, suggesting upside potential from current levels.
  • Piper Sandler reaffirmed its 'overweight' rating and set a specific price target of $270.00 on the stock.
Risk Factors
  • Wall Street Zen downgraded STERIS from a 'strong-buy' to a 'buy' rating, reflecting a slight cooling in analyst enthusiasm.
  • KeyCorp reduced its price objective from $291.00 to $269.00, indicating some analysts see limited near-term upside.
  • The stock is currently trading below its 200-day simple moving average of $233.10, which can signal short-term weakness or consolidation.
  • Insider selling activity was recorded as VP John Adam Zangerle and Director Richard C. Breeden sold shares totaling over $600,000 combined.
Full Analysis
STERIS plc (NYSE: STE) saw significant institutional activity in the first quarter, characterized by a sharp reduction in holdings by Krilogy Financial LLC, which cut its stake by 65.7% to just 1,752 shares worth $385,000. Conversely, major financial institutions increased their positions; Goldman Sachs Group Inc. grew its stake by 32.3% to acquire over 59,000 shares valued at approximately $55 million, while Jones Financial Companies Lllp and Woodline Partners LP also raised their holdings significantly. The company's stock performance metrics indicate a current trading price of $215.59, trading below its 200-day moving average of $233.10 but above its 50-day average of $212.77. Financial health remains robust with a market capitalization of $21.01 billion, a current ratio of 2.09, and a low debt-to-equity ratio of 0.25. The company recently paid a quarterly dividend of $0.63 per share, resulting in an annualized yield of 1.2% with a payout ratio of 31.78%. Analyst sentiment is mixed but generally leans positive, with an average rating of 'Moderate Buy' and a consensus price target of $278.00. While Wall Street Zen lowered its rating from 'strong-buy' to 'buy' and KeyCorp reduced its price objective, Piper Sandler maintains an 'overweight' rating with a $270 target. Insider trading activity included sales by VP John Adam Zangerle and Director Richard C. Breeden, who executed transactions under pre-arranged Rule 10b5-1 plans.